血脂康对不稳定型心绞痛患者血浆白细胞介素-6和肿瘤坏死因子α水平的影响

Effects of Xuezhikang on plasma interlekin-6 and tumor necrosis factor α in patients with unstable angina pectoris

目的研究血脂康对不稳定型心绞痛(UAP)患者抗炎抗氧化治疗的效果。方法采用酶联免疫吸附法(ELISA)测定61例UAP患者(UAP组)服用血脂康前后和40例冠脉造影正常者(对照组)白细胞介素-6(IL-6)及肿瘤坏死因子α(TNF-α)血浆浓度。结果UAP组血浆IL-6、TNF-α水平为(25.03±6.31)pg/L和(21.35±4.39)μg/L,与对照组(19.87±5.98)pg/L和(16.67±4.29)μg/L相比有显著性差异(P均<0.01),服用血脂康4周后UAP组血浆IL-6及TNF-α水平明显下降。结论血脂康在抑制UAP患者炎症反应、稳定动脉粥样斑块、减少急性心血管事件方面可能有一定的作用。

Objective It is to explore the anti-inflammatory and anti-oxidation effect of Xuezhikang in patients with unstable angina pectoris. Methods Plasma IL - 6 and TNF - α were determined by enzyme linked immunosorbent （ELISA） before and after oral administration of Xuezhikang in 61 patients with unstable angina pectoris and in 40 healthy people （ control group） whose coronary angiography were normal. Results The levels of plasma IL- 6, TNF -α were （25.03 ± 6.31）pg/ Land （21.35 ± 4.39 ） μg/L in UAP group, and those of control group were （ 19.87 ± 5.98 ） pg/L, （ 16.67 ± 4.29 ） μg/L respectively. There were significant differences between the two groups（P 〈 0.01 ）. A significant decrease of plasma IL- 6, TNF -α were observed after 4 weeks＇ of treatment with Xuezhikang（P 〈 0.01 ）. Conclusion Xuezhikang has anti-inflammatory effect and can increase stability of atherosclerotic plaque and reduce cardiovascular attacks in patients with unstable andgina pectoris.